James Blanchard

TL;DR: Evidence is provided from a non-human primate model that a therapeutic vaccine applied to the tonsils can maintain low viral loads after cessation of ART, providing support for the potential benefit of mucosally delivered vaccines in therapeutic immunization strategies for control of AIDS virus infection.

TL;DR: The SJCRH multi-vectored, multi-envelope vaccine has now been shown to elicit HIV-1-specific B- and T-cell functions with a diversity and durability that may be required to prevent HIV- 1 infections in humans.

TL;DR: In this paper, the authors reported the findings of four cases of cryptosporidiosis involving multiple organs (including the respiratory tract) in young rhesus monkeys experimentally infected with SIV/Delta at the Delta Regional Primate Research Center.

TL;DR: Results show that SHIVSF162P3N can successfully transmit across the genital mucosa, undergo coreceptor switch, and induce disease, but with lower efficiencies compared to intravenous and rectal transmissions.

TL;DR: The combined use of a topical microbicide to lower the initial viral seeding/spread and a T-cell-based vaccine to immunologically contain the early virological events of mucosal transmission holds promise as a preventive approach to control the spread of the AIDS epidemic.